Tag:

Transgene

Latest Headlines

Latest Headlines

Transgene, Jennerex ponder fate of tumor-fighting virus after PhIIb failure

Transgene expected the European commercialization rights to Jennerex's oncolytic virus immunotherapy JX-594 to eventually be worth more than $1 billion. But a Phase IIb trial for the drug has now failed the primary endpoint of overall survival in advanced liver cancer patients.

Sanofi beefs up CMO game with Transgene deal

France's Sanofi is expanding its contract manufacturing capabilities, teaming up with Transgene to spend $13 million on a new CMO platform.

French biotech rapidly stuck on losing side of hep C revolution

French biotech Transgene has watched partnership prospects vanish for its experimental vaccine against hepatitis C over the past year, as all-oral regimens against the liver-damaging disease have quickly taken over as the future therapy of choice.

PsiOxus launches human tests of cancer vaccine

PsiOxus Therapeutics began human clinical trials of its cancer vaccine ColoAd1--a highly potent anti-cancer therapeutic that destroys tumor cells at minute concentrations.

Inovio, Transgene and ChronTech enter HepC pact

Using a variation of the typical booster shot vaccination process, Inovio Pharmaceuticals, Transgene and ChronTech Pharma have joined together for a Phase I study of a therapeutic hepatitis C

R&D realignment prompts Roche to dump Transgene HPV pact

Roche has decided to exit its pact to develop and commercialize TG4001 (RG3484), a therapeutic vaccine to treat high grade cervical intraepithelial neoplasia lesions caused by human papillomavirus

Roche pulls out of Transgene vaccine pact

Roche has decided to exit its pact to develop and commercialize TG4001 (RG3484), a therapeutic vaccine to treat high grade cervical intraepithelial neoplasia lesions caused by human papillomavirus

Transgene teams with Jennerex in $116M cancer pact

France's Transgene is hitching its wagon and a $116 million slate of milestones to a new collaboration with San Francisco-based Jennerex on a virus-based cancer cell-killing therapy. In the pact the

Novartis offers $955M deal to snare Transgene drug option

Novartis has put up $10 million and promised up to €700 million more in milestones in exchange for an option on Transgene's promising, late-stage cancer immunotherapy. France's Transgene will

Is Transgene closing in on a major collaboration?

Analysts are eager to see France's Transgene nail down a licensing pact for the promising lung cancer vaccine TG4010. Pierre Corby, an analyst at Aurel BGC, told Bloomberg two weeks ago that he had